234 related articles for article (PubMed ID: 21270755)
1. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
[TBL] [Abstract][Full Text] [Related]
2. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
[TBL] [Abstract][Full Text] [Related]
3. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.
Hollick JJ; Rigoreau LJ; Cano-Soumillac C; Cockcroft X; Curtin NJ; Frigerio M; Golding BT; Guiard S; Hardcastle IR; Hickson I; Hummersone MG; Menear KA; Martin NM; Matthews I; Newell DR; Ord R; Richardson CJ; Smith GC; Griffin RJ
J Med Chem; 2007 Apr; 50(8):1958-72. PubMed ID: 17371003
[TBL] [Abstract][Full Text] [Related]
4. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
[TBL] [Abstract][Full Text] [Related]
5. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E
Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin.
Christodoulopoulos G; Muller C; Salles B; Kazmi R; Panasci L
Cancer Res; 1998 May; 58(9):1789-92. PubMed ID: 9581813
[TBL] [Abstract][Full Text] [Related]
9. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
[TBL] [Abstract][Full Text] [Related]
10. Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy.
Crescenzi E; Palumbo G; de Boer J; Brady HJ
Clin Cancer Res; 2008 Mar; 14(6):1877-87. PubMed ID: 18347191
[TBL] [Abstract][Full Text] [Related]
11. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
[TBL] [Abstract][Full Text] [Related]
12. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
14. Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses.
Fan JR; Huang TH; Wen CY; Shen TL; Li TK
Eur J Pharmacol; 2010 Jul; 638(1-3):13-20. PubMed ID: 20406630
[TBL] [Abstract][Full Text] [Related]
15. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
16. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.
de la Fuente MT; Casanova B; Moyano JV; Garcia-Gila M; Sanz L; Garcia-Marco J; Silva A; Garcia-Pardo A
J Leukoc Biol; 2002 Mar; 71(3):495-502. PubMed ID: 11867687
[TBL] [Abstract][Full Text] [Related]
17. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
[TBL] [Abstract][Full Text] [Related]
18. Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.
Vilpo J; Koski T; Vilpo L
Haematologica; 2000 Aug; 85(8):806-13. PubMed ID: 10942926
[TBL] [Abstract][Full Text] [Related]
19. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response.
Golding SE; Rosenberg E; Neill S; Dent P; Povirk LF; Valerie K
Cancer Res; 2007 Feb; 67(3):1046-53. PubMed ID: 17283137
[TBL] [Abstract][Full Text] [Related]
20. Emodin, aloe-emodin and rhein induced DNA damage and inhibited DNA repair gene expression in SCC-4 human tongue cancer cells.
Chen YY; Chiang SY; Lin JG; Yang JS; Ma YS; Liao CL; Lai TY; Tang NY; Chung JG
Anticancer Res; 2010 Mar; 30(3):945-51. PubMed ID: 20393018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
